A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Target Oncol · 2023 · PMC10663259 · PMID 37875771

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

PFS based on investigator assessment showed a trend to favour the combination treatment arm (unadjusted HR, 0.76; 95% CI 0.49–1.19).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.